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The pathogenesis of autoimmune complications triggered by SARS-CoV2 has not been
completely elucidated. Here, we performed an analysis of the cellular immune status, cell
ratios, and monocyte populations of patients with COVID-19 treated in the intensive care
unit (ICU) (cohort 1, N = 23) and normal care unit (NCU) (cohort 2, n = 10) compared with
control groups: patients treated in ICU for noninfectious reasons (cohort 3, n = 30) and
patients treated in NCU for infections other than COVID-19 (cohort 4, n = 21). Patients in
cohort 1 presented significant differences in comparison with the other cohorts, includ-
ing reduced frequencies of lymphocytes, reduced CD8+T-cell count, reduced percentage of
activated and intermediatemonocytes and an increased B/T8 cell ratio. Over time, patients
in cohort 1 who died presented with lower counts of B, T, CD4+T, CD8+T-lymphocytes, NK
cells, and activated monocytes. The B/T8 ratio was significantly lower in the group of sur-
vivors. In cohort 1, significantly higher levels of IgG1 and IgG3 were found,whereas cohort
3 presented higher levels of IgG3 compared to controls. Amongmany immune changes, an
elevated B/T8-cell ratio and a reduced rate of activated monocytes were mainly observed
in patients with severe COVID-19. Both parameters were associated with death in
cohort 1.
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Introduction
Since its outbreak in December, 2019 the Corona Virus Disease
2019 (COVID-19), caused by the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), has been responsible for hun-
dreds of thousands of deaths worldwide. Even though the virus
directly targets the respiratory tract, the immune response trig-
gered by the infection, also called the host response, can provide
further explanation for the development of severe disease with
multiple complications such as thromboembolic events, liver fail-
ure, and autoimmune manifestations [1, 2].
Viral replication in infected cells causes cell death, leading to
activation of alveolar epithelial cells and alveolar macrophages,
resulting in a local inflammatory response. The release of proin-
flammatory cytokines from these cells, such as interleukin 6
(IL-6), interferon (IFN)-γ, monocyte chemoattractant protein-1
(MCP1), and Interferon gamma-induced protein 10 (IP-10) [3,
4], further stimulates a type 1 helper T cell (Th1) response, with
migration of T lymphocytes and monocytes to the site of infection.
Whereas this immune reaction is responsible for viral clearance
in the majority of individuals, many patients with severe disease
present an abnormal immune cell activation with overexpression
of proinflammatory cytokines leading to the so called cytokine
release syndrome [1, 3–5]. This overshooting inflammation, sim-
ilar to septic disease, can lead to organ damage and death.
Lymphopenia has been described as an important character-
istic and is of prognostic value in patients with COVID-19 [4,
6, 7] since it seems to be more pronounced in patients with a
severe course of disease [8–10]. Of note, T cells appear to be par-
ticularly reduced in patients with severe disease [5]. CD8+ and
CD4+ T cells are markedly reduced in patients with a complicated
course and are also being identified as independent risk factors
for poor prognosis [5, 11–13]. Furthermore, SARS-CoV-2 infec-
tion seems to induce a differentiation of CD4+ T lymphocytes into
pathogenic Th1 cells with high expression of GM-CSF and IFN-
γ. This cytokine milieu, is also involved in the differentiation of
intermediate monocytes (CD14+, CD16+), whose presence could
accelerate tissue damage [14, 15]. However, the role of monocytic
activation in viral infections, especially in COVID-19, is yet to be
determined.
Most research efforts focusing on COVID-19 are describing
the immune reaction associated with SARS-CoV-2 extensively
but data comparing COVID-19 patients with healthy subjects
and control patients suffering from infections and diseases other
than COVID-19 is sparse. Thus, it remains unknown whether the
reported immune dysregulation is specific to COVID-19 patients
or if it can also be attributed to reactions of the immune system
provoked by severe illness in general.
In addition, as compared to T cells, the role of B cells in the
pathogenesis especially of severe disease has been less character-
ized so far. Studies have established that levels of specific circulat-
ing antibodies seem to be higher in patients with severe disease
[16] which may be due to causal linkage to antibody-dependent
immune enhancement.
Due to the fundamental role of immune cells in COVID-19 and
their prognostic importance, our study aimed to further charac-
terize the changes in lymphocyte and monocyte populations over
time as well as other parameters such as immunoglobulin profile,
C reactive protein (CRP), IL-6, and ferritin in European patients
with severe and mild COVID-19. To further elucidate whether
these changes are specific to COVID-19, we compared these data
to patients treated in the normal care unit (NCU) and intensive
care unit (ICU) for other reasons than COVID-19 in a university
hospital in Germany.
Results
Mean age was similar in all groups with longest
hospitalization times in the ICU COVID+ cohort
In total, 87 patients were included in the study and divided into
four different cohorts: cohort 1 contained 24 patients treated in
the ICU for COVID-19 (ICU COVID+), cohort 2 contained 10
patients in the NCU with COVID-19 (NCU COVID+), cohort 3
consisted of 30 patients treated in the ICU for other reasons
than COVID 19 (ICU COVID-), and cohort 4 included 21 patients
treated in the NCU for an infection other than COVID-19 (NCU
COVID-). Table 1 summarizes patient characteristics and treat-
ment parameters of all cohorts. The ICU COVID+ cohort had
the longest hospitalization time with an average time of 38 days,
whereas cohort 4 (NCU COVID−) had the shortest time of hos-
pitalization with only 5 days. The highest percentage of male
patients with 87.5% was found in the ICU COVID+ cohort.
COVID-19 patients present different immunoglobulin
profiles
Initial laboratory parameters were collected and compared
between the cohorts ICU COVID+ (cohort 1) versus ICU COVID−
(cohort 3), ICU COVID+ (cohort 1) versus NCU COVID+ (cohort
2), and NCU COVID+ (cohort 2) versus NCU COVID− (cohort
4). Table 2 summarizes the comparisons between all groups. The
ICU COVID+ cohort showed the most severe absolute lymphope-
nia among all groups, with numerically lower counts of CD4+ T
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Table 1. Patient characteristics and treatment parameters
ICU COVID+ NCU COVID+ ICU COVID- NCU COVID-
Total, n 24 10 30 21
Age, mean (years)
a
65 61 68 66
Male, n (%) 21 (87.5) 7 (66%) 23 (76%) 11 (53%)
Mechanical ventilation 21 (87.5%) 0 14 (43%) 0
Extracorporal circulation 8 (33%) 0 0 0











Nephrological disorders 1 1
Pulmonary disorders 1 0
Other 1 3
COVID-19 Spectrum
Mild COVID-19 1 4
Pneumonia 2 4
Moderate ARDS 7 0
Severe ARDS 14 0
Asymptomatic 0 2





Previous 2 3 0 2
During the study
b
20 2 0 1
a
Differences are not statistically significant.
b
Most patientswith severe disease received hydroxychloroquine. Steroidswere not administered routinely, thus, only a small proportion of patients
received it during the study. In the ICU COVID+ Cohort 1, patient received Tocilizumab.
c
Five patients had evidence of Aspergillus sp. in the bronchoscopy and one patient had evidence of Candida sp. in the blood culture.
lymphocytes, CD8+ T lymphocytes, B lymphocytes, and NK lym-
phocytes. However, the frequency of B lymphocytes was highest
in the ICU COVID+ group.
We also found significant differences in the immunoglob-
ulin concentrations at baseline between COVID patients and
non-COVID patients. ICU COVID+ patients had higher con-
centrations of IgM (119.1 vs. 60.5 mg/dL, p = 0.002), IgG1
(758.6 vs. 557.3 mg/dL, p = 0.008), and IgG3 (59.6 vs.
26.43 mg/dL, p = 0.006) in comparison with ICU COVID-
patients. Additionally, NCU COVID+ patients showed higher lev-
els of IgG3 (49.2 vs. 25.5 mg/dL, p = 0.02) in comparison
with NCU COVID– patients. There were no significant differ-
ences between both COVID+ cohorts or with regard to outcome
(Table 2).
ICU COVID+ patients show more pronounced CD8+ T
lymphopenia and higher B/T8 cell ratios
Comparisons between cohorts 1 (ICU COVID+) and 3 (ICU
COVID-) showed significant differences in CRP levels (180 vs.
119 mg/l, p = 0.03), percentage of lymphocytes (7 vs. 13 %,
p = 0.02), T-lymphocyte count (475 vs. 784 cells/μL, p = 0.02)
and percentage (67 vs. 74%, p = 0.04), CD4+ T-lymphocyte
count (359 vs. 533 cells/μL, p = 0.04) and platelets (239 vs. 182
platelets/nL, p = 0.01), respectively. CD8+ T lymphopenia was
observed in both groups, but was significantly more pronounced
in the ICU COVID+ group (114 vs. 232 cell/μL, p = 0.01).
An exploratory analysis of the B cell to CD8+ T cell ratio
showed a significant difference between ICU COVID+ and ICU
COVID− patients (1.80 vs. 0.98, p = 0.01).
Intermediate and activated monocytes are consumed
in the ICU COVID+ cohort
Comparing percentages of monocytes, the ICU COVID+ cohort
showed significantly lower rates of intermediate monocytes com-
pared to the ICU COVID− group (5.6 vs. 13%, p < 0.01), which
was also true for activated HLA-DR/CD14 positive monocytes (17
vs. 34 %, p < 0.01).
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Complex immune changes are observed in ICU
COVID+ but not in NCU COVID+ patients
Comparisons between ICU COVID+ and NCU COVID+ patients
showed significant differences in leukocyte counts (11 641 vs.
7438 cells/μL, p < 0.01), proportion of lymphocytes (7 vs. 20%,
p < 0.01), percentage of B lymphocytes (22 vs. 7.6%, p < 0.01),
and CD4+ lymphocytes (50 vs. 40%, p < 0.01), absolute CD8+ T
lymphocyte count (114 vs. 494 cells/μL, p < 0.01), proportion of
CD8+ T lymphocytes (16 vs. 31%, p < 0.01), and T4/T8 ratio (4.3
vs. 1.5, p < 0.01). In addition, we found significant differences in
CRP (180 vs. 37 mg/L, p < 0.01) and hemoglobin levels (10 vs.
13 g/dL, p < 0.01). Marked differences not reaching significance
were observed for lymphocyte counts (700 vs. 1467 cell/μL, p =
0.09), T lymphocytes (475 vs. 1130 cell/μL, p = 0.09), CD4+ T
lymphocytes (359 vs. 602 cells/μL, p = 0.25), and NK cells (79
vs. 199 cells/μL, p = 0.07).
Evaluating monocyte subsets, ICU COVID+ patients as com-
pared to NCU COVID+ patients showed a significant smaller per-
centage of intermediate monocytes (5.6 vs. 14%, p = 0.03) as
well as activated HLA-DR/CD14 positive monocytes (17 vs. 40%,
p < 0.01).
The exploratory analysis of the B cell to CD8+ T cell ratio
showed a significant difference between COVID positive patients
treated in the ICU and the NCU (1.8 vs. 0.34, p < 0.01).
NCU COVID+ (cohort 2) versus NCU COVID− (cohort 4)
Comparisons between baseline laboratory findings of cohorts 2
versus 4 revealed differences in CD4+ lymphocyte proportion (40
vs. 54%, p = 0.01), percentage of CD8+ lymphocytes (31 vs. 19%,
p = 0.01), T4/T8 ratio (1.5 vs. 3.9, p = 0.01), B/T8 ratio (0.34
vs. 0.67, p = 0.03), and the frequency of monocytes (5.0 vs. 10%,
p = 0.04).
Patients in the ICU COVID+ cohort with dismal
outcome showed impaired immune recovery
Longitudinal measures were only performed in cohort 1 due to
the longer time of hospitalization. In this group, a subgroup anal-
ysis compared patients with a favorable course of disease who
were discharged from hospital due to clinical improvement (pos-
itive outcome) with patients who died due to COVID-19 (nega-
tive outcome). Figures 1 and 2 summarize the linear regressions
from this cohort (ICU COVID+). Total leucocyte count, B lympho-
cyte count, total monocytes, classical monocytes, and intermedi-
ate monocytes showed no significant changes over time.
Linear regression analysis of absolute cell counts of lympho-
cytes, T lymphocytes, CD4+ T cells, CD8+ T cells, and NK cells
as well as percentage of activated (HLA-DR+) lymphocytes and
monocytes showed a significant increase in respective values
toward normalization. On the opposite, this was not observed
for nonclassical monocyte and B-lymphocyte percentages, which
decreased over time. Also, cell ratios of T4/T8 and B/T8 declined
significantly during the study period.
Patients with dismal outcome presented with more
pronounced immune changes compared to survivors
A larger proportion of patients in the positive outcome group
reached normalization of lymphocytes and its subpopulations
than in the group of patients with negative outcome (Table 3).
However, a small proportion of patients in the positive outcome
group did not achieve normalization of cell counts before hospital
discharge. In the group with negative outcome, only one patient
reached a normal CD8+ T-lymphocyte count. The positive out-
come group showed faster normalization of all cell populations
(Table 3, Fig. 3). In the ICU COVID+ group with favorable
outcome, it took 12 days for lymphocytes, 2.9 days for B cells,
7.3 days for CD4 T cells, 19 days for CD8 T cells, and 3.4 days
for NK cells to recover. Since only one patient in the group with
negative outcome reached normal counts of CD8 lymphocytes,
we performed a comparison of the time to a twofold increase,
which was also shorter in the group of survivors.
The comparisons were made using the mixed-effects model
for repeated measures and showed no significant interactions of
outcome and cell count or cell ratio over time. Therefore, no sig-
nificant differences between graphs were observed. Significant
interactions between outcome and cell count were observed for
lymphocytes, T lymphocytes, and CD8+ T lymphocytes (p = 0.02,
0.02, and 0.04, respectively). For CD4+ T lymphocytes (p = 0.08)
and B lymphocytes (p = 0.06), interactions between outcome and
cell count failed to show significance. Figure 3 shows cell counts,
cell ratios, and cell frequencies according to outcome over time in
specific time intervals until day 20.
A comparative analysis of the mean values of all parame-
ters collected over time showed significant differences between
patients with positive and negative outcomes with respect to leu-
cocytes (14 466 vs. 12 294 cells/μL), lymphocytes (1183 vs.
993 cells/μL), B lymphocytes (887 vs. 631 cells/μL), CD4+ lym-
phocytes (572 vs. 442 cells/μL), CD8 lymphocytes (294 vs. 172
cells/μL), NK cells (141 vs. 105 cells/μL), T4/T8 ratio (3 vs. 3.9)
HLA-DR+CD14+ monocytes (31.1 vs. 21.6%), and B/T8 ratio
(0.93 vs. 1.16). We also found lower concentrations of IL 6 (624
vs. 1560 pg/mL), ferritin (1253 vs. 2295 μg/L), and CRP (125.6
vs. 197.6 g/dL) in the positive outcome group as well as higher
platelet counts (262.9 vs. 178.4/nL). Table 4 provides a summary
of pooled analyses of all parameters.
Discussion
The immune changes during COVID-19 have been shown to
play an important role, especially in severe disease. However,
most studies conducted, thus, far have compared COVID-19
patients with healthy subjects. To address this issue, we designed
a prospective cohort study including four patient cohorts. We
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Figure 1. Lymphocyte variations over time in the ICU COVID+ Cohort. Spaghetti plots represent individual variations over time. Single points
represent individual counts/frequencies of cells over time. All linear regressions show p < 0.05 for slopes different than zero, except for leucocytes
and B lymphocytes for which the variation over time was not statistically significant. LLN, lower limit of normal. Samples were collected twice
weekly until hospital discharge due to improvement or death. For every sample, one single experiment was performed since measurements were
integrated into our routine diagnostic procedures. Each point in the plot corresponds to the measurements performed from one sample (N = 24
patients).
collected comprehensive immune cell data and serological param-
eters from all patient cohorts at the time of hospital admission.
Data collection over time was only feasible for patients treated
for severe COVID-19 in the ICU since cohorts 2, 3, and 4 had
considerably shorter times of hospitalization. Interestingly, two of
the parameters that were only identified in patients with severe
COVID-19 during baseline measurements (elevated B/T8 ratio
and low percentage of activated monocytes) were also found to
correlate with poor prognosis in this patient cohort.
In our comparisons of baseline immunological parameters
both ICU cohorts (ICU COVID+ and COVID-) showed general
lymphopenia as well as T cell and CD8+ T-cell lymphopenia,
with more severe changes observed in the ICU COVID+ cohort.
CD4+ lymphopenia was only observed in the ICU COVID+ group.
Even though some of these differences were not significant, these
results are in line with recently published data [13, 14, 17, 18]. It
is known that patients undergoing severe illness may develop non-
viral lymphopenia, and studies have shown that for ICU patients
persistent nonviral lymphopenia is an independent risk factor
for 28-day mortality [19, 20]. However, viral pathways and host
response triggered by SARS-CoV2 seem to induce a more spe-
cific and complex pattern of changes, which is supported by our
data. The mechanisms involving immune dysfunction, especially
of T lymphocytes, seem to be multifactorial and associated with
a complex context of overstimulation, excessive migration, cell
exhaustion, and simultaneous inhibition [4, 9, 14, 21–23]. More-
over, patients with severe disease seem to have higher levels of
SARS-CoV2-specific CD4+ T lymphocytes [24, 25], as well as lym-
phocytes with reduced cytotoxic activity [26].
Even though the ICU COVID+ cohort presented with a
marginally reduced absolute B-lymphocyte count, relative counts
showed higher B-cell frequencies in comparison to all other
groups, leading to the assumption of increased B-cell activity.
Similar findings have been reported by others, also demonstrating
higher frequencies of B cells in patients with severe disease as
compared to patients with milder disease [10]. Since in cohort 1,
the CD8+ T lymphocytes were reduced to a greater extent com-
pared with other cell populations, we performed an explorative
© 2021 The Authors. European Journal of Immunology published by
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Figure 2. Monocyte and cell ratio variations over time in the ICU COVID+ Cohort. Plots represent cell ratio and cell variation over time. Single
points represent individual counts/frequencies of cells over time. All linear regressions show p < 0.05 for slopes different than zero, except for
monocyte count, monocyte frequency, intermediate monocytes, and classical monocytes for which the variation over time was not statistically
significant. Samples were collected twice weekly until hospital discharge due to improvement or death. For every sample, one single experiment
was performed as part of our routine diagnostic workup. Each point in the plot corresponds to the measurements performed from one sample.
Data shown for cell ratios are from N = 24 patients and for monocytes are from N = 15 patients. The smaller sample size in monocytes is due to
COVID-19 related supply shortages of diagnostic material.
analysis of the B/T8 ratio, which showed differences between the
ICU COVID+ (cohort 1) and ICU COVID- (cohort 3) groups as well
as between the groups ICU COVID+ (cohort 1) and NCU COVID+
(cohort 2), suggesting that higher ratios could not only predict a
more severe course of disease, but also illustrate more precisely
the immune changes caused by SARS-CoV2. Interestingly, the
pooled analysis of all measures over time in ICU COVID+ sub-
groups also showed a higher B/T8 ratio in the group with dismal
outcome, which could help to understand the involvement of B
cells in severe COVID-19. Even though neutralizing antibodies
play an important role in viral clearance and immunity, the
overstimulation of B cells and the production of non-neutralizing
antibodies may lead to antibody-dependent enhancement (ADE)
worsening the infection [27, 28]. Moreover, non-neutralizing
antibodies can lead to formation of immune complexes, favoring
complement activation and tissue damage [28]. Recent reports of
patients undergoing B-cell depleting therapies provide interesting
insights into the roles of B cells in the disease. Even though a pro-
longed course has been reported, many patients developed only
mild disease, despite their underlying hematological diseases [23,
29]. All our patients presented an inversion of the ratio (from
>1 to <1) over time with a trend toward immune reconstitution,
suggesting that immune dysfunction is more pronounced at early
stages. In addition, the immunoglobulin profile in COVID patients
could also be linked to overshooting immune response. In our
study, we found statistically significant higher levels of IgG3
and IgG1 in patients with COVID compared to controls. Both
IgG subclasses are known to be linked with intensification of
inflammation with enhanced complement activation [26]. Even
though we could not find differences between both COVID+
cohorts, these findings support the development of an intrinsic
proinflammatory, complement-activating immunoglobulin milieu
and agree with recent published data [26]. Even though almost
all patients in the ICU COVID+ cohort received immunomod-
ulatory agents, mainly hydroxychloroquine, our results agree
with most of the literature published, thus far, following the
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Total patients 15 8
Lymphocytes 12 (7.7) 9 (60%) 22 (5.3) 3 (37.5%)
B lymphocytes 2.9 (4.9) 10 (66%) 5.0 (5.8) 4 (50%)
T lymphocytes 12 (9.4) 10 (66%) 23 (7) 2 (25%)
CD4+ T lymphocytes 7.3 (7) 12 (80%) 16 (20) 5 (62.5%)
CD8+ T lymphocytesb 19 (7) 6 (40%) 52 (0) 1 (12.5%)
CD8+ T lymphocytes
(twofold increase)
12 (12) 12 (80%) 20 (18) 6 (75%)
NK cells 3.4 (10) 10 (66%) 8.8 (2.9) 5 (62.5%)
a
Only patients reaching normal values were included in this analysis. Single abrupt elevations followed by abnormal values were not counted as
normalization.
b
Only one patient in the group with negative outcome reached normal CD8+ values.
In the group with positive outcome, two patients were lost to follow-up after hospital discharge with only two measures at the point of censoring.
Normal values according to local laboratory definitions: Lymphocytes > 1500 cells/μL, B lymphocytes > 150/μL, T lymphocytes > 950/μL, CD4+ T
lymphocytes > 550/μL, CD8+ T lymphocytes > 500/μL, NK cells > 80/μL.
SD, standard deviation.
conclusion that these drugs probably did not influence the
observed results. Hydroxychloroquine is known to have an
immunomodulatory effect, rather than immunosuppressive
and it is mainly prescribed in systemic lupus erythematosus,
which is a complex autoimmune disease with predominance of
autoantibodies [30]. Our findings support an important role of
B lymphocytes in severe COVID-19, which was found despite the
use of hydroxychloroquine. Steroids were used in only a small
percentage of patients and for short periods, rendering them
unlikely to have influenced our results.
Previous work suggested that the cytokine environment in
patients with severe disease stimulates intermediate monocytes
Figure 3. Comparisons of parameters per outcome over time until day 20. Graphs show cell counts or cell frequencies in four different time points
for two subgroups of the ICUCOVID+ cohort. Blue dots aremeans of the subgroupwith positive outcome (survival) (N= 16) and black dots aremeans
of the subgroup with negative outcome (death) (N = 8). Comparisons made using mixed effect model showed no significant differences between
curves. A statistically significant interaction of cell count and outcome was verified for lymphocytes, T lymphocytes, and CD8+ lymphocytes.
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Patients (n) 15 8
Leukocytes
a




Lymphocytes (%) 26.7 7.7 0.15








Activated T lymphocytes (%) 18.7 17.7 0.589
CD4+ lymphocytes (%) 49.6 51.3 0.340
CD4+ lymphocytesa 572 442 <0.01
CD8+ lymphocytes (%) 21.4 17.5 0.01
CD8+ lymphocytesa 294 172 <0.01








Monocytes (%) 5.1 5.5 0.962
HLA-DR+CD14+ Monocytes (%) 31.1 21.6 0.036
Classical monocytes (%) 83 80.8 0.310
Intermediate monocytes (%) 7.4 7.2 0.793
Nonclassical monocytes (%) 2.4 1.7 0.242
C Reactive Protein (g/dL) 125.6 197.6 <0.01
Thrombocytes
a
2 62 900 1 78 400 <0.01
Hamoglobin (g/dL) 8.6 8.5 0.89
Interleukin 6 (pg/mL) 624 1560 <0.01
Ferritin (μg/L) 1253 2295 <0.01
B/T8 0.93 1.16 0.045
a
Values shown are mean cells/μL.
Bold values represent statistic significant comparisons.
p values are not adjusted for multiple comparisons.
(CD14+/CD16+) enhancing inflammation and tissue damage
[15]. In our data, we could not demonstrate increased cell counts
of intermediate monocytes. In contrast, intermediate monocytes
and activated monocytes (HLA-DR+/CD14+) were reduced in
the ICU COVID+ cohort in comparison to the other groups when
measured at baseline. Since many patients were referred to our
hospital in an already critically-ill condition, monocyte measure-
ments were probably performed at a time point during the dis-
ease course when tissue damage was already established through
migrated monocytes. Interestingly, activated monocytes increased
significantly over time, which may favor the notion of “consump-
tion” of these cells in the earlier stages of disease, which is in
line with other recent published data [31]. In contrast to this,
nonclassical monocytes (CD14-, CD16+) were increased in the
ICU COVID+ cohort with decreasing trend over time. Notably,
the subgroup of ICU COVID+ patients with negative outcome
had lower counts of monocytes at baseline compared to sur-
vivors, which might indicate tissue migration. When comparing
activated monocytes over time, ICU COVID+ patients with favor-
able outcome showed higher counts than patients with negative
outcome.
The limitations of our study include the small sample size,
especially of the NCU COVID+ collective, which was due to the
structure of care implemented in Germany, with our center receiv-
ing mainly complex and severe cases. For the same reason, our
baseline measures at the day of hospital admission often do not
correspond to the onset of symptoms, which could have provided
important information about the immune changes at the early
stages of the disease.
Notwithstanding these limitations, we were able to demon-
strate that the immune changes induced by COVID-19 follow a
specific dynamic profile and even though some characteristics
may be similar to severe disease in general, SARS-CoV2 infec-
tion has distinct features. The T-cell compartment is particularly
affected and dramatic changes in CD8+ and CD4+ T lymphocytes
might play a prognostic role. Moreover, monocytic subsets and the
dynamics of these cells appear to correlate with outcome. Addi-
tionally, we present the B/T8 ratio as novel marker of immune
changes in severe COVID-19 and report a complement-activating
immunoglobulin profile in COVID patients. Considering this
immune profile of COVID-19, we suggest that monitoring the
immune changes in T-cell compartments, monocytes, the B/T8
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ratio, as well as immunoglobulin subclasses could be a useful tool
in monitoring the disease course. Our findings might potentially
be helpful in the future decision-making process of immune
modulatory therapies, based on the specific level of immune
dysfunction.
Materials and Methods
Study design and patients
We performed a prospective cohort study assessing the immune
response in four patient cohorts admitted to the Saarland Uni-
versity Medical Center from March 2020 to July 2020. Patients
were followed up until death or hospital discharge, or until the
end of July 2020. One patient was still hospitalized by the time of
final censoring and was counted as survivor. Cohorts 1 and 2 con-
sisted of hospitalized patients diagnosed with SARS-CoV-2 infec-
tion, confirmed by reverse transcriptase polymerase chain reac-
tion (RT-PCR) from nasopharyngeal swabs, admitted to the ICU
(cohort 1 = ICU COVID+) or NCU (cohort 2 = NCU COVID+),
respectively.
Cohort 3 (ICU COVID-) comprised hospitalized patients admit-
ted to ICU from April 2020 until July 2020 without COVID-19
infection, confirmed by negative RT-PCR results in nasopharyn-
geal swabs. Diagnosis at admission was variable between patients
and no specific inclusion criteria were used in this cohort. Cohort
4 (NCU COVID-) included patients admitted to the NCU between
April 2020 and July 2020 for reasons other than SARS-CoV-2.
Cohorts 3 and 4 served as control groups.
Patients undergoing chemotherapy or with active hematologi-
cal malignancies were excluded from the cohorts.
Patient characteristics included age, sex, presence of comor-
bidities, time of hospitalization, and number of patients in need
of mechanical ventilation or extracorporeal membrane oxygena-
tion (ECMO) at any point during the observation period. Acute
respiratory distress syndrome (ARDS) was defined and classified
according to the Berlin definition [32] with categorization into
mild (PaO2/FiO2 200 to 300 mmHg), moderate (PaO2/FiO2 100
to 200 mmHg), and severe (PaO2/FiO2 less than 100 mmHg).
The study was part of the CORSAAR register study and was
approved by the Ethics Committee of Saarland University, Hom-
burg, Germany.
Immune characterization and laboratory parameters
Measurements of leucocytes, hemoglobin, and platelets were per-
formed using a Sysmex XN-LTM automated hematology analyzer.
Immune characterization of lymphocytes was performed by
flowcytometry using a BD FACSCantoTM II cell analyzer. Flow
cytometry was performed according to the “Guidelines for the
use of flow cytometry and cell sorting in immunological stud-
ies” [33]. Monocyte subpopulations were characterized using a
Beckman–Coulter NaviosTM Analyzer. Total counts of lymphocytes
and monocyte subpopulations were therefore calculated using a
dual-platform system. Tests were performed twice weekly until
hospital discharge due to clinical improvement or death. Cel-
lular parameters included lymphocytic differentiation into NK
cells (CD56+, CD16+), B lymphocytes (CD19+), T lymphocytes
(CD3+), CD4+ T lymphocytes (CD3+, CD4+), and CD8+ T lym-
phocytes (CD3+, CD8+), as well as differentiation of monocytes
into the subsets classical, intermediate, and nonclassical (CD14+
CD16-, CD14+ CD16+, CD14- CD16+). Of note, monocyte mea-
surements were repeatedly interrupted throughout the study due
to COVID-19 related supply shortages of diagnostic antibodies
resulting in gaps of monocyte data.
Cell ratios of B cells to CD8+ cells and of CD4+ to CD8+ T
lymphocytes were calculated from total cell counts of each patient
and are given as mean of all individual ratios.
Laboratory parameters included complete blood cell count,
CRP, Ferritin, and IL-6 and were also obtained twice weekly until
hospital discharge due to clinical improvement or death. The level
of immunoglobulins IgA, IgM, IgG, and IgG subclasses (1, 2, 3,
and 4) were measured once at baseline.
Statistical analysis
Data were collected using Microsoft® Excel® 2016. Statisti-
cal analyses were performed using GraphPad Prism version 8.0
(GraphPad Software, San Diego, CA, USA). Trends over time were
analyzed using linear regression. Comparisons per outcome over
time were analyzed using repeated measures mixed-effect mod-
els. Nonparametric tests (Mann–Whitney U) were used to com-
pare median ranks between groups, because most variables were
not distributed normally. Comparisons between cohorts were per-
formed using baseline values. Comparisons per outcome in the
ICU COVID+ group (cohort 1) were performed at baseline and
as pooled analysis of all individual values collected over time. For
this, cohort 1 was divided into two groups of patients with positive
outcome (discharge from hospital due to clinical improvement)
and patients with negative outcome (death due to COVID-19).
Baseline was determined as the date of admission to NCU or ICU,
which does not necessarily correspond to the onset of symptoms.
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